Allovir

Yahoo Finance • 2 years ago

AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., January 03, 2023--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st An... Full story

Yahoo Finance • 2 years ago

Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting

WALTHAM, Mass., November 03, 2022--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of cli... Full story